| Evaluation of a conservative treatment with iloprost in severe peripheral occlusive arterial disease (POAD). GISAP Study. | |
| | |
MedLine Citation:
|
PMID: 7521384 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
GISAP, a multicentre open study, was aimed to confirm the feasibility and safety of iloprost treatment in normal clinical practice and to identify subgroups of patients with severe POAD more likely to benefit from iloprost treatment than others. One hundred forty six patients were treated at the maximum tolerated dose of iloprost up to 2 ng/kg/min, 6 hours infusion per day, for a minimum of 3 weeks and a maximum of 8 weeks. Clinical efficacy was assessed by rest pain reduction, analgesic consumption, healing of trophic lesions, walking ability. A significant improvement of the efficacy parameters was recorded during and at the end of treatment: no difference between diabetics and non diabetics, stage III and IV patients was observed. After one year follow-up 10% major amputation and 6.8% death were recorded, these events were balanced between the diabetic and non diabetic patients. Overall 80% of the patients at risk of amputation at entry to the trial were alive with a viable limb after one year. Tolerability resulted quite acceptable. Even with the limitation of an open trial, it has been confirmed the therapeutic potential of iloprost in the treatment of POAD patients. |
| | |
Authors:
|
- |
Related Documents
:
|
15676314 - Comparison of continuous infusion versus midwife administered top-ups of epidural bupiv... 12766654 - A multicenter, randomized, controlled trial comparing bupivacaine with ropivacaine for ... 15245634 - Comparison of symptoms of younger and older patients undergoing coronary artery bypass ... 19696704 - Oral transmucosal fentanyl citrate: a novel analgesic agent for use in retinal photocoa... 18636544 - Chronic anorexia nervosa: a delphi study to explore practitioners' views. 23279054 - Compliance to the consort statement of randomized controlled trials in solid organ tran... |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Multicenter Study |
Journal Detail:
|
Title: International angiology : a journal of the International Union of Angiology Volume: 13 ISSN: 0392-9590 ISO Abbreviation: Int Angiol Publication Date: 1994 Mar |
Date Detail:
|
Created Date: 1994-10-05 Completed Date: 1994-10-05 Revised Date: 2004-11-17 |
Medline Journal Info:
|
Nlm Unique ID: 8402693 Medline TA: Int Angiol Country: ITALY |
Other Details:
|
Languages: eng Pagination: 70-4 Citation Subset: IM |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Aged, 80 and over Arterial Occlusive Diseases / drug therapy* Diabetes Complications Female Humans Iloprost / therapeutic use* Male Middle Aged Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
78919-13-8/Iloprost |
| Comments/Corrections | |
Erratum In:
|
Int Angiol 1994 Dec;13(4):356 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Iloprost, stable analogue of the prostacyclin, is able to improve the tissue resistance to ischaemia...
Next Document: Hepatic lipase gene is transcribed in rat adrenals into a truncated mRNA.